Drug Profile
Research programme: neurological disorders therapeutics - MindImmune Therapeutics
Latest Information Update: 28 Jun 2022
Price :
$50
*
At a glance
- Originator Lundbeck A/S
- Developer MindImmune Therapeutics
- Class
- Mechanism of Action Kynurenine 3-monooxygenase inhibitors; Purinergic P2X7 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Huntington's disease; Neuropathic pain
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for preclinical development in Neuropathic-pain in USA
- 28 Aug 2020 No recent reports of development identified for preclinical development in Huntington's-disease in USA
- 22 May 2018 Preclinical trials in Huntington's disease in USA (unspecified route)